Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=26055221
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 278.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 278.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 278.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26055221
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 J+Allergy+Clin+Immunol
2015 ; 136
(5
): 1178-85
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Radiation-sensitive severe combined immunodeficiency: The arguments for and
against conditioning before hematopoietic cell transplantation--what to do?
#MMPMID26055221
Cowan MJ
; Gennery AR
J Allergy Clin Immunol
2015[Nov]; 136
(5
): 1178-85
PMID26055221
show ga
Defects in DNA cross-link repair 1C (DCLRE1C), protein kinase DNA activated
catalytic polypeptide (PRKDC), ligase 4 (LIG4), NHEJ1, and NBS1 involving the
nonhomologous end-joining (NHEJ) DNA repair pathway result in radiation-sensitive
severe combined immunodeficiency (SCID). Results of hematopoietic cell
transplantation for radiation-sensitive SCID suggest that minimizing exposure to
alkylating agents and ionizing radiation is important for optimizing survival and
minimizing late effects. However, use of preconditioning with alkylating agents
is associated with a greater likelihood of full T- and B-cell reconstitution
compared with no conditioning or immunosuppression alone. A reduced-intensity
regimen using fludarabine and low-dose cyclophosphamide might be effective for
patients with LIG4, NHEJ1, and NBS1 defects, although more data are needed to
confirm these findings and characterize late effects. For patients with mutations
in DCLRE1C (Artemis-deficient SCID), there is no optimal approach that uses
standard dose-alkylating agents without significant late effects. Until
nonchemotherapy agents, such as anti-CD45 or anti-CD117, become available,
options include minimizing exposure to alkylators, such as single-agent low-dose
targeted busulfan, or achieving T-cell reconstitution, followed several years
later with a conditioning regimen to restore B-cell immunity. Gene therapy for
these disorders will eventually remove the issues of rejection and
graft-versus-host disease. Prospective multicenter studies are needed to evaluate
these approaches in this rare but highly vulnerable patient population.